Life science company Acucort highlights in its September newsletter previously published studies on Zeqmelit, the company’s dexamethasone oral film.In a survey of 426 patients, 72 percent said they would prefer an oral film to tablets in the event of a severe allergic reaction. A separate health economics study also showed a higher willingness to pay for oral film compared with traditional tablet treatment.The company points to the scientific publications as support for efforts to establish Zeqmelit in more markets.